Weight-loss and Diabetes Drugs Associated with Rare Eye Conditions and Vision Risks
TL;DR
Recent studies suggest that GLP-1 agonists like Ozempic and Wegovy may slightly increase the risk of serious eye conditions such as NAION and diabetic retinopathy, but they also offer significant benefits for managing diabetes and obesity. Regular eye exams and careful risk assessment are recommended for users, especially those with pre-existing risk factors. Ongoing research aims to better understand these risks and improve patient safety.
- Ozempic and other weight-loss drugs linked to rare but serious eye conditions The Conversation
- New Research Confirms Weight-Loss Drug Link With Sudden Vision Loss ScienceAlert
- Popular Diabetes Drugs Linked to Small Risk of Retinal, Optic Nerve Disorders MedPage Today
- Study Counters Others on GLP-1, Diabetic Retinopathy Link Medscape
- Study links weight-loss drugs to serious eye conditions and vision loss The Independent
Want the full story? Read the original reporting
Read on The Conversation